Zydus Lifesciences Shares Surge Up to 5% on Strong Q3 FY26 Results

sciences Limited saw its shares jump as much as 5% in intraday trading on February 9, 2026, following the announcement of robust third-quarter results for FY26. The stock hit an intraday high before closing around 4% higher. The pharmaceutical company reported a consolidated net profit of ₹1,042 crore for Q3 FY26, reflecting a modest 2% year-on-year (YoY) increase from ₹1,023.5 crore in the same quarter of the previous year. This figure was impacted by a one-time exceptional cost of ₹84.9 crore related to the implementation of new labour codes. Adjusted for this exceptional item, the profit showed stronger underlying performance, with reports indicating an approximate 9% YoY rise in normalized net profit. Revenue from operations delivered impressive growth, surging over 30% YoY to ₹6,864.5 crore (approximately ₹6,865 crore) from ₹5,269.1 crore in Q3 FY25. This strong top-line expansion was supported by solid contributions across key segments, including pharmaceuticals, consumer wellness, and medtech, as well as momentum in the US and India markets. EBITDA rose 30.9% YoY to ₹1,816.4 crore, with the EBITDA margin improving slightly to 26.5% from 26.3% in the prior year, highlighting operational efficiency gains.